Intravitreal rituximab
Intravitreal rituximab is an ophthalmic use of rituximab, a monoclonal anti-CD20 antibody, administered by injection into the vitreous cavity of the eye.
Intravitreal rituximab is an ophthalmic use of rituximab, a monoclonal anti-CD20 antibody, administered by injection into the vitreous cavity of the eye. In this setting, it is used as a local therapy to deliver B-cell–directed treatment directly to intraocular disease sites, rather than through systemic administration. Its principal biomedical relevance is in ocular conditions in which B-cell malignancy or immune-mediated pathology is present within the eye, especially vitreoretinal lymphoma.
As a localized route of administration, intravitreal rituximab is intended to achieve therapeutic exposure in ocular tissues while limiting systemic effects. In recent literature, it has been studied mainly as a salvage or adjunctive treatment in relapsed vitreoretinal lymphoma, including cases occurring after prior ocular radiotherapy.
Where the papers sit
10 papers from the last 6 months study intravitreal rituximab directly · updated from PubMed 28 Sept 2026
Study type 3 clinical trials · 6 observational · 1 human data
Themes 3 themes
-
Rituximab-Based Lymphoma Treatment
Lymphoma treatment ranges from durable lenalidomide–rituximab therapy in relapsed indolent disease to intravitreal rituximab salvage for vitreoretinal lymphoma. Ocular disease remains a specialized setting alongside systemic non-Hodgkin lymphoma care. Infusion-related reactions remain a practical concern, prompting evaluation of antihistamine prophylaxis. Survival and relapse control, rather than a single treatment strategy, recur across the work.
3 papers · 30%
-
Rituximab in Autoimmune Disease
Rituximab treatment is moving toward response-guided management across membranous nephropathy and neuromyelitis optica spectrum disorder. Proteinuria and M-type phospholipase A2 receptor status help determine treatment need and response in kidney disease. FCGR2A and FCGR3A variants may explain differences in therapeutic efficacy. In neuromyelitis optica, treatment is assessed not only by relapse control but also by longitudinal spinal cord atrophy.
3 papers · 30%
-
Others — B-Cell Depletion Therapy
Rituximab is used across aggressive lymphoma and rare immune-mediated disorders, with B-cell depletion serving as the shared therapeutic rationale. Polatuzumab vedotin plus R-CHP is being applied to very elderly patients with diffuse large B-cell lymphoma. Other reports emphasize rituximab consolidation for immune-mediated neurologic disease and treatment of post-transplant pure red cell aplasia. The cluster remains clinically heterogeneous, with no single disease-specific direction.
4 papers · 40%
Papers
The 10 papers from the last 6 months that study intravitreal rituximab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Rituximab-Based Lymphoma Treatment (3)
- Successful use of intravitreal rituximab as salvage therapy for relapsed vitreoretinal lymphoma. Indian journal of ophthalmology · 27 May 2026 PMID 42200736
- Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 16 Apr 2026 PMID 41990300
- Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial. International journal of clinical oncology · 16 Apr 2026 PMID 41989666
Rituximab in Autoimmune Disease (3)
- The value of proteinuria for the administration of rituximab in patients with PLA2R-associated membranous nephropathy: a single-centre retrospective analysis. Annals of medicine · 5 Jun 2026 PMID 42247284
- Longitudinal Spinal Cord Atrophy in Patients With Neuromyelitis Optica Spectrum Disorder and Its Association With Rituximab Treatment. Neurology · 1 Jun 2026 PMID 42224638
- Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases. Pharmacology research & perspectives · 22 May 2026 PMID 42170767
Others — B-Cell Depletion Therapy (4)
- Clinical Outcomes of Pola-R-CHP Therapy in Patients Aged >80 Years With Diffuse Large B-Cell Lymphoma. Anticancer research · 29 Jun 2026 PMID 42373284
- Relapsing Seronegative Immune-Mediated Cerebellar Ataxia with Evolving Intrathecal Immune Activation and Rituximab Consolidation in a Toddler: A Case Report. Cerebellum (London, England) · 26 Jun 2026 PMID 42360526
- Immunotherapy for Fertility in Autoimmune Premature Ovarian Insufficiency. NEJM evidence · 23 Jun 2026 PMID 42334299
- Pure Red Cell Aplasia Associated With Recipient B-Cell Mixed Chimerism Successfully Treated With Rituximab. Pediatric transplantation · 30 May 2026 PMID 42216498
By study type
Clinical trials (3)
- Immunotherapy for Fertility in Autoimmune Premature Ovarian Insufficiency. NEJM evidence · 23 Jun 2026 PMID 42334299
- Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 16 Apr 2026 PMID 41990300
- Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial. International journal of clinical oncology · 16 Apr 2026 PMID 41989666
Observational studies and case reports (6)
- Clinical Outcomes of Pola-R-CHP Therapy in Patients Aged >80 Years With Diffuse Large B-Cell Lymphoma. Anticancer research · 29 Jun 2026 PMID 42373284
- Relapsing Seronegative Immune-Mediated Cerebellar Ataxia with Evolving Intrathecal Immune Activation and Rituximab Consolidation in a Toddler: A Case Report. Cerebellum (London, England) · 26 Jun 2026 PMID 42360526
- The value of proteinuria for the administration of rituximab in patients with PLA2R-associated membranous nephropathy: a single-centre retrospective analysis. Annals of medicine · 5 Jun 2026 PMID 42247284
- Longitudinal Spinal Cord Atrophy in Patients With Neuromyelitis Optica Spectrum Disorder and Its Association With Rituximab Treatment. Neurology · 1 Jun 2026 PMID 42224638
- Pure Red Cell Aplasia Associated With Recipient B-Cell Mixed Chimerism Successfully Treated With Rituximab. Pediatric transplantation · 30 May 2026 PMID 42216498
- Successful use of intravitreal rituximab as salvage therapy for relapsed vitreoretinal lymphoma. Indian journal of ophthalmology · 27 May 2026 PMID 42200736
Human data, design not indexed (1)
- Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases. Pharmacology research & perspectives · 22 May 2026 PMID 42170767
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.